This is the authors' abstract. We don't add key points for this paper.
Sir, In a previous study we demonstrated that doripenem, the most recently approved carbapenem, exhibited antimicrobial activity similar to that of imipenem or meropenem in an experimental rabbit model of susceptible Pseudomonas aeruginosa pneumonia.1 Mutational inactivation of oprD is known to be the main mechanism of imipenem resistance in the absence of acquired carbapenemase. Although oprD inactivation also increases the MICs of meropenem and doripenem, clinical resistance to these drugs is thought to require additional mechanisms.2 In this work we compared the efficacy of doripenem versus imipenem or meropenem against a resistant oprD-inactive strain of P. aeruginosa in an experimental model. The experimental rabbit model of pneumonia has been described previously.3 The bacterial strain was a ΔoprD PAO1, which is resistant to carbapenems after inactivation of OprD porin, a carbapenem-specific transport porin.4 This strain was provided by courtesy of Professor P. Plésiat, Besançon, France. MICs of meropenem, doripenem and imipenem were 8, 1 and 16 mg/L, respectively. Antibiotics were delivered through a venous catheter, with changing infusion rates determined by computer-controlled electric pumps, in order to simulate the pharmacokinetics observed in human serum.5
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bretonnière et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: